Trial Profile
A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Brain metastases; Germ cell and embryonal neoplasms; Germ cell cancer
- Focus Therapeutic Use
- Acronyms CABA-GCT
- 21 Sep 2021 Status changed from recruiting to completed as per the results presented at the 46th European Society for Medical Oncology Congress.
- 11 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 25 Jun 2014 New trial record